New hope for advanced cancer patients? early trial of SB17170 begins
NCT ID NCT05522868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called SB17170 in about 50 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for signs that the drug might slow tumor growth. Participants take SB17170 capsules daily in 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SB17170 (oral capsules)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact